Covid and cholesterol (C&amp;C): Something to worry about or much ado about nothing?

Garg, Heena; Khanna, Puneet

doi:10.1016/j.tacc.2020.09.003

Cited by 7 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We suppose that increased activity of PPARG as the key regulator of transcription activity of STAB1 and CD36 as receptors for modified LDL in the virus-infected areas may lead to greater lipid uptake and transient lipid depletion. This is consistent with the finding that serum lipid levels, namely total cholesterol, HDL-cholesterol, and LDL-cholesterol in patients with COVID-19 infection were significantly lower and associated with poor prognosis [ 63 ]. Several underlying mechanisms were suggested, including decreased LDL biosynthesis due to liver dysfunction, altered lipid metabolism because of acute inflammation, and/or lipid degradation induced by elevated free radicals [ 63 ].…”

Section: Discussionsupporting

confidence: 91%

“…This is consistent with the finding that serum lipid levels, namely total cholesterol, HDL-cholesterol, and LDL-cholesterol in patients with COVID-19 infection were significantly lower and associated with poor prognosis [ 63 ]. Several underlying mechanisms were suggested, including decreased LDL biosynthesis due to liver dysfunction, altered lipid metabolism because of acute inflammation, and/or lipid degradation induced by elevated free radicals [ 63 ].…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Transcriptomic Profiles Reveal Downregulation of Low-Density Lipoprotein Particle Receptor Pathway Activity in Patients Surviving Severe COVID-19

Vlasov

Пантелеева

Usenko

et al. 2021

Cells

View full text Add to dashboard Cite

To assess the biology of the lethal endpoint in patients with SARS-CoV-2 infection, we compared the transcriptional response to the virus in patients who survived or died during severe COVID-19. We applied gene expression profiling to generate transcriptional signatures for peripheral blood mononuclear cells (PBMCs) from patients with SARS-CoV-2 infection at the time when they were placed in the Intensive Care Unit of the Pavlov First State Medical University of St. Petersburg (Russia). Three different bioinformatics approaches to RNA-seq analysis identified a downregulation of three common pathways in survivors compared with nonsurvivors among patients with severe COVID-19, namely, low-density lipoprotein (LDL) particle receptor activity (GO:0005041), important for maintaining cholesterol homeostasis, leukocyte differentiation (GO:0002521), and cargo receptor activity (GO:0038024). Specifically, PBMCs from surviving patients were characterized by reduced expression of PPARG, CD36, STAB1, ITGAV, and ANXA2. Taken together, our findings suggest that LDL particle receptor pathway activity in patients with COVID-19 infection is associated with poor disease prognosis.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

Transcriptomic Profiles Reveal Downregulation of Low-Density Lipoprotein Particle Receptor Pathway Activity in Patients Surviving Severe COVID-19

Vlasov

Пантелеева

Usenko

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…Associations with hospitalisation or death due to COVID-19 were also not observed for current smoking and a higher coronary artery calcium score. Previous studies on the association of smoking, hypertension, lipid levels and coronary artery calcium score with COVID-19 outcomes have yielded mixed findings 8 14–18…”

Section: Discussionmentioning

confidence: 99%

Association of cardiometabolic risk factors with hospitalisation or death due to COVID-19: population-based cohort study in Sweden (SCAPIS)

et al. 2021

View full text Add to dashboard Cite

ObjectiveTo assess the association of cardiometabolic risk factors with hospitalisation or death due to COVID-19 in the general population.Design, setting and participantsSwedish population-based cohort including 29 955 participants.ExposuresCardiometabolic risk factors assessed between 2014 and 2018.Main outcome measuresHospitalisation or death due to COVID-19, as registered in nationwide registers from 31 January 2020 through 12 September 2020. Associations of cardiometabolic risk factors with the outcome were assessed using logistic regression adjusted for age, sex, birthplace and education.ResultsMean (SD) age was 61.2 (4.5) and 51.5% were women. 69 participants experienced hospitalisation or death due to COVID-19. Examples of statistically significant associations between baseline factors and subsequent hospitalisation or death due to COVID-19 included overweight (adjusted OR (aOR) vs normal weight 2.73 (95% CI 1.25 to 5.94)), obesity (aOR vs normal weight 4.09 (95% CI 1.82 to 9.18)), pre-diabetes (aOR vs normoglycaemia 2.56 (95% CI 1.44 to 4.55)), diabetes (aOR vs normoglycaemia 3.96 (95% CI 2.13 to 7.36)), sedentary time (aOR per hour/day increase 1.10 (95% CI 1.02 to 1.17)), grade 2 hypertension (aOR vs normotension 2.44 (95% CI 1.10 to 5.44)) and high density lipoprotein cholesterol (aOR per mmol/L increase 0.33 (95% CI 0.17 to 0.65)). Statistically significant associations were not observed for grade 1 hypertension (aOR vs normotension 1.03 (95% CI 0.55 to 1.96)), current smoking (aOR 0.56 (95% CI 0.24 to 1.30)), total cholesterol (aOR per mmol/L increase 0.90 (95% CI 0.71 to 1.13)), low density lipoprotein cholesterol (aOR per mmol/L increase 0.90 (95% CI 0.69 to 1.15)) and coronary artery calcium score (aOR per 10 units increase 1.00 (95% CI 0.99 to 1.01)).ConclusionsIn a large population-based sample from the general population, several cardiometabolic risk factors were associated with hospitalisation or death due to COVID-19.

show abstract

“…illustrated that fenofibrate inhibits replication of SARS-CoV-2 in human lung epithelial cells [ 86 ]. As well, fenofibrate attenuates SARS-CoV-2-induced up-regulation of lipogenesis and glycolysis with subsequent suppression of metabolic footprint for viral replication [ 87 ]. However, the other drugs such as metformin, rosiglitazone, and empagliflozin which have impacts on the lipogenesis and glycolysis did not affect viral replications [ 87 ].…”

Section: Fenofibrate and Covid-19mentioning

confidence: 99%

Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail

et al. 2022

View full text Add to dashboard Cite

Introduction Fenofibrate is an agonist of peroxisome proliferator activated receptor alpha (PPAR-α), that possesses anti-inflammatory, antioxidant, and anti-thrombotic properties. Fenofibrate is effective against a variety of viral infections and different inflammatory disorders. Therefore, the aim of critical review was to overview the potential role of fenofibrate in the pathogenesis of SARS-CoV-2 and related complications. Results By destabilizing SARS-CoV-2 spike protein and preventing it from binding angiotensin-converting enzyme 2 (ACE2), a receptor for SARS-CoV-2 entry, fenofibrate can reduce SARS-CoV-2 entry in human cells Fenofibrate also suppresses inflammatory signaling pathways, which decreases SARS-CoV-2 infection-related inflammatory alterations. In conclusion, fenofibrate anti-inflammatory, antioxidant, and antithrombotic capabilities may help to minimize the inflammatory and thrombotic consequences associated with SARSCoV-2 infection. Through attenuating the interaction between SARS-CoV-2 and ACE2, fenofibrate can directly reduce the risk of SARS-CoV-2 infection. Conclusions As a result, fenofibrate could be a potential treatment approach for COVID-19 control.

show abstract

Covid and cholesterol (C&C): Something to worry about or much ado about nothing?

Cited by 7 publications

References 12 publications

Transcriptomic Profiles Reveal Downregulation of Low-Density Lipoprotein Particle Receptor Pathway Activity in Patients Surviving Severe COVID-19

Transcriptomic Profiles Reveal Downregulation of Low-Density Lipoprotein Particle Receptor Pathway Activity in Patients Surviving Severe COVID-19

Association of cardiometabolic risk factors with hospitalisation or death due to COVID-19: population-based cohort study in Sweden (SCAPIS)

Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail

Contact Info

Product

Resources

About